Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment

Clearmind Medicine (Nasdaq: CMND) reported a Japanese patent application publication for MEAI-based compositions targeting depression, expanding its global intellectual property portfolio.

Rhea-AI Summary

Clearmind Medicine (Nasdaq: CMND) reported a Japanese patent application publication for MEAI-based compositions targeting depression, expanding its global intellectual property portfolio. MEAI is a non-hallucinogenic molecule intended as an alternative to SSRIs and psychedelic-based therapies.

The company highlights large and growing anxiety, depression, and broader behavioral health markets, including an estimated $16–22.65 billion global anxiety and depression market in 2025. Japan has about 3 million diagnosed MDD cases. Clearmind is also researching MEAI for alcohol use disorder, metabolic disorders such as weight loss, and other mental health indications.

Positive

• Japanese patent application publication for MEAI-based depression treatment compositions
• IP portfolio spans multiple jurisdictions with multiple granted patents and applications
• Target market for anxiety and depression estimated at $16–22.65 billion in 2025
• Broader behavioral and mental health market projected to approach $350 billion by 2035
• Japan has approximately 3 million diagnosed MDD cases, supporting market opportunity
• MEAI pipeline includes alcohol use disorder and metabolic and other mental disorders

Argus May 29 session

+46.12% close to close Open Argus

Details

News Market Reaction – CMND

On May 29, the day this news came out, CMND closed 46.12% above the previous close.

Data tracked by StockTitan Argus for the May 29 session.

Market Context

On May 29, the day this news came out, the stock closed 46.1% above the previous close. A strong pos...

Analysis

On May 29, the day this news came out, the stock closed 46.1% above the previous close. A strong positive reaction aligns with the strategic significance of expanding patent protection for MEAI into Japan’s sizeable depression market and the broader behavioral health opportunity cited at $185B in 2025. However, CMND’s history of volatile responses to news and the presence of an effective Form F-3 supporting registered resale of up to 22,626,988 shares tied to convertible notes could introduce additional supply over time, which may affect how durable any sharp upside move proves to be.

Key Figures

Anxiety/depression market 2025: $16–22.65 billion Anxiety/depression 2030-2031: $19–30 billion Behavioral & mental health 2025: $185 billion +5 more

Anxiety/depression market 2025

$16–22.65 billion

Estimated global anxiety and depression treatment market size in 2025

Anxiety/depression 2030-2031

$19–30 billion

Projected global anxiety and depression treatment market by 2030–2031

Behavioral & mental health 2025

$185 billion

Estimated broader behavioral and mental health market size in 2025

Behavioral & mental health 2035

$350 billion

Projected behavioral and mental health market size by 2035

Japan MDD cases

3 million

Diagnosed cases of Major Depressive Disorder (MDD) in Japan

Registered resale shares

22,626,988 shares

Common shares registered for resale under Form F-3 tied to CLA notes

CLA principal registered

$10.0M

Principal amount of convertible notes assumed in F-3 share calculation

Accrued interest registered

$3.576M

Accrued interest amount included in F-3 share calculation

Historical Context

5 past events · Latest: May 26

5 events

1. May 26

   Clinical trial advance

   24h Move

   +14.6%

   IRB approval at Johns Hopkins to advance CMND-100 Phase I/II trial.

2. May 19

   Reverse share split

   24h Move

   -37.8%

   1-for-10 reverse split to support Nasdaq minimum bid price compliance.

3. May 18

   Preclinical collaboration

   24h Move

   -26.9%

   Agreement to study MEAI with tirzepatide in obese mice for weight loss.

4. May 15

   Leadership recognition

   24h Move

   -1.6%

   CEO named delegate to federal psychedelic medicine policy summit.

5. May 12

   Clinical milestone

   24h Move

   +3.8%

   20 participants treated in Phase I/IIa CMND-100 trial for AUD.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

5-methoxy-2-aminoindan, selective serotonin reuptake inhibitors, ssris, major depressive disorder, +3 more

7 terms

5-methoxy-2-aminoindan medical

"proprietary compositions comprising 5-Methoxy-2-aminoindan (MEAI) for the treatment"

A small synthetic chemical that belongs to the aminoindan family and affects brain signaling chemicals; it has been studied mainly as a research compound rather than an approved medicine. Investors should care because such compounds can represent early-stage drug candidates or regulatory liabilities: if a company owns or licenses activity around it, the compound’s safety profile, legal status, and potential therapeutic value can materially influence development costs, approval chances, and market value — like an experimental prototype that could become a product or a costly hurdle.

selective serotonin reuptake inhibitors medical

"Current treatments, primarily selective serotonin reuptake inhibitors (SSRIs) and other"

Selective serotonin reuptake inhibitors are a common class of prescription drugs used to treat depression and certain anxiety disorders by helping the brain keep more of a chemical called serotonin, which can improve mood. Think of them like a dimmer switch that helps maintain a steadier light level rather than abrupt flickers. Investors track them because their approval, patent status, safety profile, and sales can materially affect drugmakers’ revenues and stock value.

ssris medical

"Current treatments, primarily selective serotonin reuptake inhibitors (SSRIs) and other"

Selective serotonin reuptake inhibitors (SSRIs) are a class of prescription medicines that raise levels of the brain chemical serotonin by preventing its reabsorption into nerve cells. Think of them like closing a small drain so more water stays in a bathtub: they help mood-regulating signals last longer. Investors watch SSRIs because their sales, patent status, safety data and prescribing trends can strongly affect drugmakers’ revenue and regulatory risk.

major depressive disorder medical

"The country has approximately 3 million diagnosed cases of Major Depressive Disorder"

A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.

mdd medical

"The country has approximately 3 million diagnosed cases of Major Depressive Disorder (MDD)."

Major depressive disorder (MDD) is a medical condition characterized by persistent low mood, loss of interest in daily activities, and impaired functioning similar to carrying a heavy backpack that makes ordinary tasks much harder. For investors, MDD matters because treatments and therapies for it are a large market regulated by health authorities; clinical trial outcomes, approvals, or safety concerns can strongly affect a drugmaker’s sales prospects, valuation, and risk profile.

intellectual property regulatory

"This advancement strengthens Clearmind’s robust intellectual property portfolio, which already"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

neuroplastogen medical

"second-generation, neuroplastogen-derived therapeutics to solve major under-treated health"

A neuroplastogen is a drug or compound designed to boost the brain’s ability to rewire and form new connections, enhancing recovery or adaptation after injury, stress, or disease. For investors, these molecules matter because they target underlying brain repair processes rather than just masking symptoms, offering the potential for durable benefits in conditions like depression, neurodegeneration, or cognitive decline—akin to giving a tired garden fresh tools to regrow and reshape itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of a Japanese Patent Application for its proprietary compositions comprising 5-Methoxy-2-aminoindan (MEAI) for the treatment of depression.

This advancement  strengthens Clearmind’s robust intellectual property portfolio, which already includes multiple granted patents and applications worldwide. MEAI, the company’s flagship non-hallucinogenic molecule, is designed to offer a safer, more accessible alternative to traditional antidepressants and emerging psychedelic-based therapies.

Depression remains one of the leading causes of disability worldwide. Current treatments, primarily selective serotonin reuptake inhibitors (SSRIs) and other conventional antidepressants, often come with limitations including delayed onset of action, side effects, and high rates of treatment resistance.

The global market for anxiety and depression treatments is experiencing steady growth. Estimates place the market size at approximately $16- 22.65 billion in 2025, with projections reaching $19–30 billion by 2030- 2031, driven by rising mental health awareness, increasing prevalence of disorders, and demand for innovative therapies. The broader behavioral and mental health market is significantly larger, valued at around $185 billion in 2025 and expected to approach $350 billion by 2035.

In Japan, mental health challenges are pronounced due to societal factors such as work-related stress. The country has approximately 3 million diagnosed cases of Major Depressive Disorder (MDD).

Clearmind continues to expand its MEAI-based pipeline, with ongoing research into alcohol use disorder, metabolic disorders such as weight loss, and various other mental disorders. The company’s IP portfolio now spans multiple jurisdictions, reinforcing its position in the rapidly evolving neuroplastogen and mental health therapeutics space.

About Clearmind Medicine Inc.    

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected growth of the global market for anxiety and depression treatments and the behavioral and mental health market and how the Company continues to expand its MEAI-based pipeline, with ongoing research into alcohol use disorder, metabolic conditions, and other mental disorders. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clearmind Medicine (NASDAQ: CMND) announce on May 29, 2026?

Clearmind Medicine announced publication of a Japanese patent application for its MEAI-based depression treatment compositions. According to Clearmind, this filing strengthens its growing intellectual property portfolio across multiple jurisdictions in the neuroplastogen and mental health therapeutics field.

What is MEAI in Clearmind Medicine's depression treatment pipeline for CMND stock investors?

MEAI is Clearmind’s flagship non-hallucinogenic molecule designed to treat depression. According to Clearmind, it aims to provide a safer, more accessible alternative to traditional antidepressants and emerging psychedelic-based therapies, addressing issues like side effects, delayed onset, and treatment resistance.

How large is the global anxiety and depression treatment market mentioned by Clearmind Medicine (CMND)?

Clearmind cites estimates that the global anxiety and depression treatment market is about $16–22.65 billion in 2025. According to Clearmind, projections suggest this market could reach roughly $19–30 billion by 2030–2031, driven by rising awareness and demand for innovative therapies.

Why is Japan an important market for Clearmind Medicine's MEAI depression treatment (CMND)?

Japan is highlighted due to pronounced mental health challenges and work-related stress factors. According to Clearmind, the country has approximately 3 million diagnosed Major Depressive Disorder (MDD) cases, making it a significant potential market for MEAI-based depression therapies.

What other indications is Clearmind Medicine exploring for MEAI beyond depression for CMND shareholders?

Clearmind is researching MEAI for alcohol use disorder, metabolic disorders such as weight loss, and other mental disorders. According to Clearmind, these programs expand the MEAI-based pipeline within the broader behavioral and mental health therapeutics space across multiple jurisdictions.

How does the Japanese patent filing affect Clearmind Medicine's intellectual property strategy for CMND?

The Japanese patent application publication adds another jurisdiction to Clearmind’s MEAI-related intellectual property. According to Clearmind, this step reinforces a robust patent portfolio that already includes multiple granted patents and applications worldwide in neuroplastogen-derived mental health therapeutics.